Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib in PIK3CA-mutated Tumors (MATCH Subprotocol Z1F)
NCT05490771Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2018
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of copanlisib in lymphoma, malignant solid neoplasm, multiple myeloma (MM), sponsored by National Cancer Institute. Started Jun 2018; status: active, not recruiting.
02
Drugs
copanlisib
03
Conditions
lymphomamalignant solid neoplasmmultiple myeloma (MM)
Beyond the preview
Go deeper on NCT05490771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05490771.